Dendritic Cell (DC)-Tumor Cell Fusion Service: Pioneering Hybrid Immunotherapy

Online Inquiry

At Creative Biolabs, we specialize in cutting-edge Dendritic Cell (DC)-Tumor Cell Fusion services that combine the immunostimulatory potential of dendritic cells with the tumor-specific antigens from cancer cells. By creating hybrid cells that present a broad array of tumor antigens, our service enhances both innate and adaptive immune responses, offering a promising strategy for cancer immunotherapy. Through our advanced fusion techniques, we enable the development of personalized cancer vaccines and immune therapies that are more effective in recognizing and targeting cancer cells.

DC-Tumor Cell Fusion Services at Creative Biolabs

Tumor RNA Pulsed Dendritic Cell (DC) Development Service: Harnessing Intracellular Antigen

Our Tumor RNA Pulsed Dendritic Cell (DC) Development Service focuses on harnessing the power of RNA to enhance tumor antigen presentation. By pulsing dendritic cells with tumor-derived RNA, we facilitate the direct uptake and processing of intracellular antigens, enabling DCs to present a more diverse range of tumor markers. This service increases the likelihood of immune activation against intracellular and mutated proteins that are often missed in traditional antigen-presentation methods.

Learn More →

Tumor Lysate Pulsed Dendritic Cell (DC) Development Service: Comprehensive Antigen Presentation

The Tumor Lysate Pulsed Dendritic Cell (DC) Development Service utilizes tumor lysates to load dendritic cells with a comprehensive profile of antigens from the tumor. Tumor lysates contain both membrane-bound and intracellular tumor antigens, providing DCs with a full range of tumor markers. This method ensures that the immune system can recognize and target not only surface proteins but also the hidden intracellular antigens, which are crucial for the elimination of solid tumors.

Learn More →

Autophagosome Pulsed Dendritic Cell (DC) Development Service: Enhancing Cross-Presentation of Tumor Antigen

Our Autophagosome Pulsed Dendritic Cell (DC) Development Service is designed to enhance the cross-presentation of tumor antigens by dendritic cells. By pulsing DCs with autophagosomes, which contain tumor-derived intracellular proteins, we promote the processing of these antigens via the cross-presentation pathway. This service ensures that both CD8⁺ cytotoxic T cells and CD4⁺ helper T cells are activated, expanding the immune response to target a wider array of tumor antigens, including those that are otherwise poorly presented.

Learn More →

How Our DC-Tumor Cell Fusion Service Works

Phase I

Tumor Cell Preparation

Tumor cells, isolated from patient samples or allogeneic sources, are prepared and cultured under optimal conditions to preserve the unique antigens that can trigger immune recognition.

Phase II

Dendritic Cell Maturation

Dendritic cells (DCs) are isolated from peripheral blood and matured under specific conditions to enhance their antigen-presenting capabilities. These matured DCs are then loaded with tumor-specific antigens.

Phase III

Fusion Process

DCs are fused with tumor cells using advanced fusion techniques such as electrofusion or chemical fusion. This results in hybrid cells that combine the potent antigen-presenting ability of DCs with the tumor-specific markers from cancer cells.

Phase IV

Characterization and Quality Control

The fusion product is characterized to confirm its ability to activate T-cells and initiate an immune response against the tumor. Quality control ensures that these hybrid cells are both functional and effective.

Phase V

Customization for Personalized Cancer Therapies

The DC-tumor cell hybrids can be customized to the specific tumor profiles of individual patients, ensuring targeted and highly personalized immunotherapy strategies.

Why Choose Our DC-Tumor Cell Fusion Service

Comprehensive Antigen Presentation

By using multiple antigen-loading strategies—such as tumor RNA, lysates, and autophagosomes—we create DCs capable of presenting a broad spectrum of tumor-specific antigens, ensuring a more robust immune activation.

Dual Activation of Immune Responses

The DC-tumor cell fusion approach activates both the innate and adaptive immune systems, leading to a more potent and sustained anti-tumor immune response.

Personalized Immunotherapy

Our services are highly customizable, allowing us to tailor the antigen-presentation methods to the individual cancer profile, which increases the efficacy of the immunotherapy.

Advanced Technology and Expertise

At Creative Biolabs, we use state-of-the-art techniques and years of expertise in immuno-oncology to ensure the highest quality DC-tumor cell fusion products. We are committed to providing reliable, effective, and cutting-edge cancer immunotherapies.

Partner with Creative Biolabs

At Creative Biolabs, we pride ourselves on being a leader in cell-based immunotherapies. Our team's deep expertise in dendritic cell biology, tumor immunology, and hybrid cell technology allows us to offer best-in-class DC-tumor cell fusion services. Whether you are looking to develop a personalized vaccine, explore new hybrid immunotherapy strategies, or leverage cutting-edge technologies for cancer treatment, we provide the expertise and resources to bring your vision to life.
Our commitment to excellence, combined with our comprehensive approach to immune-oncology, ensures that we deliver high-quality, innovative solutions tailored to your specific needs. Please contact us for more details. Trust Creative Biolabs for your DC-Tumor Cell Fusion Service, where science meets the future of cancer immunotherapy.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.